DK3129404T3 - Immunglobuliner, der binder humane vgamma9vdelta2-t-cellereceptorer - Google Patents

Immunglobuliner, der binder humane vgamma9vdelta2-t-cellereceptorer

Info

Publication number: DK3129404T3
Authority: DK; Denmark
Prior art keywords: immunoglobulins; cell receptors; binding human; binding; human
Prior art date: 2014-04-10

Application number

DK15722781.0T

Other languages

English (en)

Inventor

Der Vliet Johannes Jelle Van

Bruin Renée Cornelia Gerarda De

Gruijl Tanja Denise De

Hendrik Marinus Willem Verheul

Original Assignee

Lava Therapeutics N V

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2014-04-10

Filing date

2015-04-10

Publication date

2026-04-20

2015-04-10 Application filed by Lava Therapeutics N V filed Critical Lava Therapeutics N V

2026-04-20 Application granted granted Critical

2026-04-20 Publication of DK3129404T3 publication Critical patent/DK3129404T3/da

Links

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/75—Agonist effect on antigen
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Immunology (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Molecular Biology (AREA)
Biochemistry (AREA)
Genetics & Genomics (AREA)
Biophysics (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Cell Biology (AREA)
Peptides Or Proteins (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Engineering & Computer Science (AREA)
Medicinal Preparation (AREA)
Urology & Nephrology (AREA)
Hematology (AREA)
Biomedical Technology (AREA)
Virology (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Tropical Medicine & Parasitology (AREA)
Biotechnology (AREA)
Zoology (AREA)
Microbiology (AREA)
Food Science & Technology (AREA)
Physics & Mathematics (AREA)
Analytical Chemistry (AREA)
General Physics & Mathematics (AREA)
Pathology (AREA)
Investigating Or Analysing Biological Materials (AREA)

DK15722781.0T 2014-04-10 2015-04-10 Immunglobuliner, der binder humane vgamma9vdelta2-t-cellereceptorer DK3129404T3 (da)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
NL2012604		2014-04-10
PCT/NL2015/050235 WO2015156673A1 (en)	2014-04-10	2015-04-10	IMMUNOGLOBULINS BINDING HUMAN Vγ9Vδ2 T CELL RECEPTORS

Publications (1)

Publication Number	Publication Date
DK3129404T3 true DK3129404T3 (da)	2026-04-20

Family

ID=50896416

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DK15722781.0T DK3129404T3 (da)	2014-04-10	2015-04-10	Immunglobuliner, der binder humane vgamma9vdelta2-t-cellereceptorer

Country Status (13)

Country	Link
US (4)	US10501540B2 (da)
EP (1)	EP3129404B1 (da)
JP (4)	JP6617138B2 (da)
KR (2)	KR102601469B1 (da)
CN (2)	CN106536557B (da)
AU (3)	AU2015244489B2 (da)
DK (1)	DK3129404T3 (da)
EA (2)	EA202192165A1 (da)
FI (1)	FI3129404T3 (da)
LT (1)	LT3129404T (da)
MX (2)	MX385333B (da)
SG (2)	SG10202007233TA (da)
WO (1)	WO2015156673A1 (da)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
IL297773B2 (en) *	2014-11-17	2024-07-01	Adicet Bio Inc	Engineered gamma delta t-cells
US10501541B2 (en)	2015-01-27	2019-12-10	Lava Therapeutics B.V.	Single domain antibodies targeting CD1d
US11299708B2 (en)	2016-05-12	2022-04-12	Adicet Bio, Inc.	Methods for selective expansion of γδ T-cell populations and compositions thereof
US10356636B2 (en) *	2017-04-03	2019-07-16	Qualcomm Incorporated	Techniques and apparatuses to improve drone-mounted user equipment performance
MX2020005005A (es)	2017-11-15	2020-08-27	Adicet Bio Inc	Métodos para la expansión selectiva de poblaciones de células t gamma delta delta 3 y composiciones de estas.
CN108659130B (zh) *	2018-05-28	2021-09-10	长春力太生物技术有限公司	一种抗癌胚抗原纳米抗体及其应用
MX2021000184A (es) *	2018-07-05	2021-05-12	Novobind Livestock Therapeutics Inc	Anticuerpos contra agentes patogenos en aves de corral y sus aplicaciones.
AU2019344300A1 (en) *	2018-09-19	2021-04-22	LAVA Therapeutics N.V.	Dual acting CD1D immunoglobulin
US12410225B2 (en)	2018-11-08	2025-09-09	Orionis Biosciences, Inc	Modulation of dendritic cell lineages
PH12021551475A1 (en)	2019-01-07	2022-05-02	Shattuck Labs Inc	Heterodimeric proteins for modulating gamma delta t cells
US11098093B2 (en)	2019-01-07	2021-08-24	Shattuck Labs, Inc.	Heterodimeric proteins for modulating gamma delta T cells
CN113993893A (zh)	2019-02-01	2022-01-28	拉法医疗有限公司	新cd40结合抗体
NL2022494B1 (en)	2019-02-01	2020-08-19	Lava Therapeutics B V	Novel CD40-binding antibodies
JP7308477B2 (ja) *	2019-03-11	2023-07-14	パナソニックＩｐマネジメント株式会社	抗体、複合体、それを用いた検出装置及び検出方法
MA55903A (fr)	2019-05-08	2022-03-16	Janssen Biotech Inc	Matières et méthodes pour moduler l'immunité médiée par les lymphocytes t
EP3792283A1 (en)	2019-09-16	2021-03-17	Lava Therapeutics B.V.	Treatment of cancer comprising administration of vgamma9vdelta2 t cell receptor binding antibodies
GB201918279D0 (en) *	2019-12-12	2020-01-29	Vib Vzw	Glycosylated single chain immunoglobulin domains
AU2021225870A1 (en) *	2020-02-27	2022-10-20	Janssen Biotech, Inc.	Materials and methods for modulating an immune response
CN115916963A (zh)	2020-03-27	2023-04-04	门德斯有限公司	白血病来源的经修饰细胞用于增强过继性细胞治疗的效力的离体用途
EP4171617A1 (en)	2020-06-30	2023-05-03	Mendus B.V.	Use of leukemia-derived cells in ovarian cancer vaccines
KR20230042035A (ko)	2020-07-08	2023-03-27	라바 테라퓨틱스 엔.브이.	Psma와 감마-델타 t 세포 수용체에 결합할 수 있는 항체
EP4237003A4 (en) *	2020-10-28	2025-07-09	Janssen Biotech Inc	COMPOSITIONS AND METHODS FOR MODULATING GAMMA DELTA CHAIN-MEDIATED IMMUNITY
CA3196677A1 (en)	2020-11-05	2022-05-12	Erik Hans MANTING	Use of tumor-independent antigens in immunotherapies
TW202225188A (zh) *	2020-11-06	2022-07-01	德商安美基研究（慕尼黑）公司	與ｃｄ３結合的多肽構建體
WO2022116952A1 (zh) *	2020-12-01	2022-06-09	苏州克睿基因生物科技有限公司	靶向cd70的抗原结合蛋白及其应用
CA3200826A1 (en)	2020-12-10	2022-06-16	Paul Willem Henri Ida PARREN	Antibodies that bind gamma-delta t cell receptors
JP2024506249A (ja)	2021-01-22	2024-02-13	メンドゥス・ベスローテン・フェンノートシャップ	腫瘍ワクチン接種の方法
BR112023017099A2 (pt)	2021-02-26	2023-11-21	Lava Therapeutics N V	Anticorpos que se ligam a cd123 e a receptores de células t gama-delta
CA3229822A1 (en)	2021-09-13	2023-03-16	Patrick John DOONAN	Cd33 x v?2 multispecific antibodies for the treatment of cancer
JP2024538958A (ja)	2021-10-21	2024-10-28	ラヴァ・セラピューティクス・エヌ・ヴイ	ガンマデルタｔ細胞活性化抗体の使用
JP2025504363A (ja) *	2022-01-05	2025-02-12	インヒブルクスバイオサイエンシズインコーポレイテッド	γδＴ細胞結合ポリペプチド及びその使用
CN114478757B (zh) *	2022-03-31	2022-07-05	深圳市人民医院	靶向新冠病毒的纳米抗体及其制备方法和应用
EP4285926A1 (en)	2022-05-30	2023-12-06	LAVA Therapeutics N.V.	Combination treatment for chronic lymphocytic leukemia
EP4292610A1 (en)	2022-06-15	2023-12-20	LAVA Therapeutics N.V.	Variant antibodies that bind gamma-delta t cell receptors
EP4292609A1 (en)	2022-06-15	2023-12-20	LAVA Therapeutics N.V.	Compositions comprising antibodies that bind gamma-delta t cell receptors
CN116178538B (zh) *	2023-01-05	2024-08-02	暨南大学	靶向热休克蛋白70的纳米抗体及其制备方法与应用
EP4665766A2 (en) *	2023-02-13	2025-12-24	LAVA Therapeutics N.V.	Combination therapy comprising multispecific gamma delta tcr antibodies
CN116284405B (zh) *	2023-03-15	2024-03-19	中国科学技术大学	靶向cd150蛋白的纳米抗体及其应用
EP4688851A1 (en)	2023-03-27	2026-02-11	LAVA Therapeutics N.V.	Nectin-4 binding agents and methods of use
EP4438624A1 (en)	2023-03-27	2024-10-02	LAVA Therapeutics N.V.	Antibodies that bind nectin-4 and gamma-delta t cell receptors
WO2025012118A2 (en)	2023-07-07	2025-01-16	LAVA Therapeutics N.V.	5t4 binding agents and methods of use
WO2025120583A2 (en)	2023-12-08	2025-06-12	Janssen Biotech, Inc.	CD33 ANTIBODIES, CD33/Vδ2 MULTISPECIFIC ANTIBODIES AND USES THEREOF
CN118496370A (zh) *	2024-06-07	2024-08-16	南方医科大学深圳医院	一种靶向alox5纳米抗体及其应用
WO2026033458A1 (en)	2024-08-08	2026-02-12	Janssen Biotech, Inc.	DOSES AND PHARMACEUTICAL COMPOSITIONS OF A CD33 X Vδ2 BISPECIFIC ANTIBODY FOR THE TREATMENT OF CANCER

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
FR2698880B1 (fr) *	1992-11-25	1995-02-24	Inst Nat Sante Rech Med	Procédé de production de récepteurs T solubles, produits ainsi obtenus et leur utilisation dans des compositions diagnostiques ou thérapeutiques.
JP2006517789A (ja) *	2003-01-10	2006-08-03	アブリンクスエン．ヴェー．	治療用ポリペプチド、その相同物、その断片、および血小板媒介凝集の調節での使用
US20060246520A1 (en) *	2003-05-23	2006-11-02	Institut National De La Sante Et De La Recherche Medicale	Gamma delta t cell-mediated therapy
CA2569509C (en) *	2004-06-03	2014-08-12	Novimmune S.A.	Anti-cd3 antibodies and methods of use thereof
ITRM20070437A1 (it) *	2007-08-10	2009-02-11	Istituto Naz Per Le Malattie I	Metodo per la generazione ed espansione di cellule t gamma/delta regolatorie cellule cosi' ottenute e loro impieghi
WO2009131730A2 (en) *	2008-01-31	2009-10-29	University Of Iowa Research Foundation	IMMUNOGENIC COMPOSITIONS FOR ACTIVATING γδ T CELLS
CN102154205A (zh) *	2011-01-31	2011-08-17	郑骏年	高纯度、高细胞毒活性的γδT细胞的制备方法
US9670275B2 (en) *	2012-01-23	2017-06-06	Ablynx N.V.	Sequences directed against hepatocyte growth factor (HGF) and polypeptides comprising the same for the treatment of cancers and/or tumors
CN103571791B (zh) *	2012-02-10	2015-05-13	深圳市合一康生物科技股份有限公司	一种人γδT细胞的形态学、纯度及免疫表型检测方法
CN104334741B (zh) *	2012-03-28	2018-08-17	歌德塔有限公司	组合的γ9δ2T细胞受体链交换

2015
- 2015-04-10 DK DK15722781.0T patent/DK3129404T3/da active
- 2015-04-10 KR KR1020227003540A patent/KR102601469B1/ko active Active
- 2015-04-10 KR KR1020167031470A patent/KR102359264B1/ko active Active
- 2015-04-10 LT LTEPPCT/NL2015/050235T patent/LT3129404T/lt unknown
- 2015-04-10 EA EA202192165A patent/EA202192165A1/ru unknown
- 2015-04-10 CN CN201580029256.8A patent/CN106536557B/zh active Active
- 2015-04-10 AU AU2015244489A patent/AU2015244489B2/en active Active
- 2015-04-10 CN CN202110414426.1A patent/CN113105550A/zh active Pending
- 2015-04-10 MX MX2016013332A patent/MX385333B/es unknown
- 2015-04-10 SG SG10202007233TA patent/SG10202007233TA/en unknown
- 2015-04-10 EP EP15722781.0A patent/EP3129404B1/en active Active
- 2015-04-10 JP JP2017505036A patent/JP6617138B2/ja active Active
- 2015-04-10 SG SG11201609417VA patent/SG11201609417VA/en unknown
- 2015-04-10 FI FIEP15722781.0T patent/FI3129404T3/fi active
- 2015-04-10 US US15/302,927 patent/US10501540B2/en active Active
- 2015-04-10 EA EA201692039A patent/EA039086B1/ru unknown
- 2015-04-10 WO PCT/NL2015/050235 patent/WO2015156673A1/en not_active Ceased
2016
- 2016-10-10 MX MX2021009674A patent/MX2021009674A/es unknown
2019
- 2019-05-16 US US16/414,424 patent/US20190263908A1/en not_active Abandoned
- 2019-11-14 JP JP2019206255A patent/JP7094931B2/ja active Active
2020
- 2020-08-05 AU AU2020213325A patent/AU2020213325B2/en active Active
2021
- 2021-10-28 US US17/513,621 patent/US11384145B2/en active Active
2022
- 2022-06-22 JP JP2022100477A patent/JP7342202B2/ja active Active
- 2022-12-15 US US18/066,791 patent/US20230212290A1/en active Pending
2023
- 2023-06-30 AU AU2023204215A patent/AU2023204215B2/en active Active
- 2023-08-30 JP JP2023140495A patent/JP7583130B2/ja active Active

Also Published As

Publication number	Publication date
JP7342202B2 (ja)	2023-09-11
US10501540B2 (en)	2019-12-10
US20220098301A1 (en)	2022-03-31
KR102601469B1 (ko)	2023-11-14
JP6617138B2 (ja)	2019-12-11
JP2023165723A (ja)	2023-11-17
MX385333B (es)	2025-03-18
SG10202007233TA (en)	2020-09-29
AU2020213325A1 (en)	2020-08-27
MX2021009674A (es)	2021-09-08
WO2015156673A1 (en)	2015-10-15
CA2948812A1 (en)	2015-10-15
AU2015244489A1 (en)	2016-12-01
AU2015244489B2 (en)	2020-08-27
FI3129404T3 (fi)	2026-04-09
MX2016013332A (es)	2017-05-01
CN106536557B (zh)	2021-05-04
EA039086B1 (ru)	2021-12-01
KR20170019343A (ko)	2017-02-21
KR102359264B1 (ko)	2022-02-04
CN113105550A (zh)	2021-07-13
EP3129404B1 (en)	2026-01-28
US20230212290A1 (en)	2023-07-06
JP2020029461A (ja)	2020-02-27
JP7583130B2 (ja)	2024-11-13
EA202192165A1 (ru)	2021-12-31
US20170029506A1 (en)	2017-02-02
JP2017513521A (ja)	2017-06-01
AU2023204215B2 (en)	2026-03-26
JP7094931B2 (ja)	2022-07-04
JP2022136078A (ja)	2022-09-15
EP3129404A1 (en)	2017-02-15
KR20220021015A (ko)	2022-02-21
AU2020213325B2 (en)	2023-03-30
US11384145B2 (en)	2022-07-12
US20190263908A1 (en)	2019-08-29
LT3129404T (lt)	2026-04-27
SG11201609417VA (en)	2016-12-29
CN106536557A (zh)	2017-03-22
AU2023204215A1 (en)	2023-07-20
EA201692039A1 (ru)	2017-05-31

Publication	Publication Date	Title
DK3129404T3 (da)	2026-04-20	Immunglobuliner, der binder humane vgamma9vdelta2-t-cellereceptorer
IL269531A (en)	2019-11-28	Improved antigen binding receptors
HRP20181802T1 (hr)	2018-12-28	Protutijela koja vežu humani cd3
PL3494133T3 (pl)	2022-11-21	Receptory limfocytów t anty-kras-g12d
DK3440106T3 (da)	2021-10-04	T-cellereceptorer
DK3440105T3 (da)	2022-06-13	T-cellereceptorer
DK3411065T3 (da)	2021-07-05	Clec9a-bindingsmidler
DK3592384T3 (da)	2025-09-15	Antistoffer, der specifikt binder til human il-1r7
DK3201230T3 (da)	2021-02-15	Canine pd-l1-bindende pd-l1-antistoffer
MA43259A (fr)	2018-09-26	Liants ctla4
DK3514172T3 (da)	2020-04-06	Claudin-6-specifikke immunoreceptorer og t-celleepitoper
DK3223845T3 (da)	2021-08-16	Heterodimere antistoffer, der binder cd3 og cd20
DK3110849T3 (da)	2020-11-23	Antistof, der binder erbb-2 og erbb-3
PL3242892T3 (pl)	2022-02-21	Zmienione przeciwciała wiążące april
DK3177646T3 (da)	2020-12-07	Cd3-bindingsdomæne
DK3362477T3 (da)	2022-03-07	Antigenbindingsproteiner, der aktiverer leptinreceptoren
EP3327220A4 (en)	2019-02-27	BINDING MACHINE
EP3506964C0 (en)	2023-08-30	BINDING SYRINGE
KR102365881B9 (ko)	2022-04-14	원예용 결속기
DK4012087T3 (da)	2024-01-02	Bindersystem
DK3613447T3 (da)	2022-01-03	Humane pancreas-scaffolds
PL3004167T3 (pl)	2019-01-31	Białka wiążące antygen receptora onkostatyny m
ME02954B (me)	2018-07-20	Poboljšana tnf veziva
KR102281534B9 (ko)	2022-04-14	원예용 결속기
EP3448520A4 (en)	2020-07-29	SIGMA RECEIVER BINDERS